Abstract Body

Background: ACTG A5175/PEARLS was a randomized trial undertaken in diverse geographic settings that showed similar outcomes for the primary endpoint of time to virologic failure, new AIDS event or death in the comparison of tenofovir/emtricitabine or zidovudine/lamivudine with efavirenz (TDF/ FTC+EFV or ZDV/3TC+EFV). We present results for a secondary objective comparing the effects of these regimens on anthropometric outcomes. Methodology: Antiretroviral naive subjects with nadir CD4 counts <300/mm3 were enrolled in Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, United States and Zimbabwe, and randomized to TDF/FTC+EFV (n=526) or ZDV/3TC+EFV (n=519). We compared changes in weight, body mass index (BMI), and mid-arm, waist, hip and mid-thigh circumferences, from baseline to 48, 96 and 144 weeks using repeated measures intent to treat analysis Results: 46% of subjects were female; median age, CD4 count and HIV-1 RNA were 34y, 159/mm3 and 5.0 log10 c/mL. Mean (sd) baseline anthropometric measures were: weight kg: 63 (14); BMI kg/m2: 23 (4); circumferences, cm: mid-arm 28 (4), waist 80 (10), hip 92 (10), mid-thigh 48 (7). 9% had BMI<18.5 (underweight); 26% had BMI≥25 (overweight). At weeks 48, 96 and 144: n=973, 941 and 902 had measurements; 35 subjects died and 106 were lost to follow-up before week 144. In both arms, there were significant increases in all anthropometric measures at each of weeks 48, 96 and 144 (figure). The increases from baseline were, however, significantly larger for TDF/FTC+EFV vs ZDV/3TC+EFV (repeated measures p<0.001 except p=0.037 for waist) with mean change at week 144: weight kg: 4.8 vs 3.0; BMI kg/m2: 1.8 vs 1.1; circumferences, cm: mid-arm 1.7 vs 0.7, waist 5.2 vs 4.3, hip 3.8 vs 1.4, mid-thigh 3.1 vs 0.9. Difference in mean BMI change between arms did not vary significantly by baseline BMI: at week 144, -0.3 vs -0.8 kg/m2 for baseline BMI <18.5, 1.0 vs 0.7 for BMI 18.5-<25; 3.1 vs 2.1 for BMI≥25. There were 7 clinical diagnoses of lipoatrophy in the ZDV/3TC+EFV arm but none in the TDF/FTC+EFV arm. Conclusions: Although the primary efficacy outcome was similar for TDF/FTC+EFV and ZDV/3TC+EFV, increases in weight, BMI and body circumferences were larger for TDF/FTC+EFV. While these findings and the lower rate of clinical lipoatrophy for TDF/FTC+EFV support current guideline recommendations for TDF/FTC+EFV as initial therapy, the greater BMI increases and hence potential for increased cardiovascular risk among overweight subjects needs consideration.